# Neil Stahl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/neil-stahl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 48,198 |
| Field | SARS-CoV-2 and COVID-19 Research |
| h-index | 84 |
| i10-index | 129 |
| Last Known Institution | Arthritis and Rheumatism Associates |
| OpenAlex ID | https://openalex.org/A5083524146 |
| ORCID iD | https://orcid.org/0000-0001-7265-2575 |
| Works | 163 |

## Researcher papers

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma](https://scholariq.org/papers/dupilumab-efficacy-and-safety-in-moderate-to-severe-uncontrolled-asthma/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-glucocorticoid-dependent-severe-asthma/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-multiple-dupilumab-dose-regimens-after-initial-successful/)

## Researcher topics

- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Prion Diseases and Protein Misfolding](https://scholariq.org/topics/prion-diseases-and-protein-misfolding/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Cytokine Signaling Pathways and Interactions](https://scholariq.org/topics/cytokine-signaling-pathways-and-interactions/)

## Researcher university

- [Arthritis and Rheumatism Associates](https://scholariq.org/institutions/arthritis-and-rheumatism-associates/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.